GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Scaled Net Operating Assets

Alliance Pharma (LSE:APH) Scaled Net Operating Assets : 0.70 (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Alliance Pharma's operating assets for the quarter that ended in Jun. 2023 was £487.6 Mil. Alliance Pharma's operating liabilities for the quarter that ended in Jun. 2023 was £112.3 Mil. Alliance Pharma's Total Assets for the quarter that ended in Dec. 2022 was £537.4 Mil. Therefore, Alliance Pharma's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was 0.70.


Alliance Pharma Scaled Net Operating Assets Historical Data

The historical data trend for Alliance Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Scaled Net Operating Assets Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 0.83 0.97 0.73 0.78

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.73 0.80 0.72 0.70

Competitive Comparison of Alliance Pharma's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Scaled Net Operating Assets falls into.



Alliance Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Alliance Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(505.697-112.174)/503.488
=0.78

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=537.411 - 31.714
=505.697

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=249.75 - 136.963 - 0.613
=112.174

Alliance Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2023 )
=(Operating Assets (Q: Jun. 2023 )-Operating Liabilities (Q: Jun. 2023 ))/Total Assets (Q: Dec. 2022 )
=(487.608-112.335)/537.411
=0.70

where

Operating Assets(Q: Jun. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=513.72 - 26.112
=487.608

Operating Liabilities(Q: Jun. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=236.761 - 123.708 - 0.718
=112.335

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q2 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amphenol Announces Third Quarter 2023 Dividend

By Business Wire 08-04-2023

The Amphenol Corp (APH) Company: A Short SWOT Analysis

By GuruFocus Research 10-30-2023

Q2 2023 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024